MedPath

New Cancer Cure-Bio Co.,Ltd.

🇰🇷South Korea
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.nccbio.co.kr/

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: KN510 120mg/day + KN713 120mg/day
Drug: KN510 60mg/day + KN713 60mg/day
Drug: KN510 120mg/day + KN713 60mg/day
Drug: KN510 120mg/day + KN713 90mg/day
First Posted Date
2023-08-25
Last Posted Date
2025-01-08
Lead Sponsor
New Cancer Cure-Bio Co.,Ltd.
Target Recruit Count
12
Registration Number
NCT06012708
Locations
🇰🇷

National Cancer Center, Goyang-si, Korea, Republic of

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.